Intravenous administration of ANX005, an anti-C1q therapy, reduced CSF antibody-driven complement activity in early-stage Guillain-Barré Syndrome

Intravenous administration of ANX005, an anti-C1q therapy, reduced CSF antibody-driven complement activity in early-stage Guillain-Barré Syndrome - Annexon Biosciences